REDWOOD BIOSCIENCE INC
- Headquarters
- EMERYVILLE, CA
- Founded
- 2008
- Latest Form D
- $2.5M, Jan 2014
- Total capital
- $13.9M
- Federal grants
- $2.4M
- 6 awards · 2009–2014
- Private capital raised
- $11.5M
- 5 Form D · last Jan 2014
- 153 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 13 pending · first 2015
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Directed Evolution of Formylglycine-generating Enzyme to Build an Optimal Platfor$136K
- Private capital raisedForm D · SEC · 5th filing$2.5M
- Private capital raisedForm D · SEC · 4th filing$8.6M
- Federal grantHealth and Human S · Phase I · Using Aldehyde Tags to Generate Site-Specifically Modified Antibody Drug Conjugat$100K
- Federal grantHealth and Human S · Phase II · Using Aldehyde Tags to Generate Site-Specifically Modified Antibody Drug Conjugat$530K
- Federal grantHealth and Human S · Phase II · Using Aldehyde Tags to Generate Site-Specifically Modified Antibody Drug Conjugat$670K
- Private capital raisedForm D · SEC · 3rd filing$300K
- Private capital raisedForm D · SEC · 2nd filing$2K
- Private capital raisedForm D · SEC · 1st filing$2K
Show 2 earlier federal awards
- Federal grantHealth and Human S · RC1 · Universal Protein Carrier Scaffold for Small Molecules and Peptide Therapeutics$500K
- Federal grantHealth and Human S · RC1 · Universal Protein Carrier Scaffold for Small Molecules and Peptide Therapeutics$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
5months
from REDWOOD BIOSCIENCE INC’s first federal award to its first private round.
- First federal award · Sep 2009
- Health and Human S · $500K
- First Form D · Mar 2010
- $2K · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- David Ian RabukaResearcherExecutive Officer, Director, PromoterLinked by 11 patents
- BARRY LITTLEJOHNSDirectorNamed in SEC Form D filings
- Carolyn Ian BertozziPromoterNamed in SEC Form D filings
- EDWARD GORDON MCCRACKENDirectorNamed in SEC Form D filings
- J GORDON FOULKESDirectorNamed in SEC Form D filings
- Karen Ian BoeziExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- MICHAEL BLANKExecutive OfficerNamed in SEC Form D filings
- Paul Ian SocolowDirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 32- GrantedHydrazinyl-Pyrrolo Compounds and Methods for Producing a ConjugateUSPTOUS 12,215,080
- GrantedAntibody Specific For CD22 And Methods Of Use ThereofUSPTOUS 12,116,409
- GrantedAnti-Her2 Antibody-Maytansine Conjugates and Methods of Use ThereofUSPTOUS 12,076,411
Show all 32 patent records
- Hydrazinyl-Pyrrolo Compounds and Methods for Producing a ConjugateFeb 4, 2025 · US 12,215,080Granted
- Antibody Specific For CD22 And Methods Of Use ThereofOct 15, 2024 · US 12,116,409Granted
- Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use ThereofSep 3, 2024 · US 12,076,411Granted
- Hydrazinyl-Indole Compounds and Methods for Producing a ConjugateMar 2, 2023 · Application 17874122Pending
- Hydrazinyl-indole Compounds And Methods For Producing A ConjugateAug 30, 2022 · US 11,426,465Granted
- Hydrazinyl-Pyrrolo Compounds and Methods for Producing a ConjugateNov 23, 2021 · US 11,180,451Granted
- ANTI-HER2 Antibody-maytansine Conjugates And Methods Of Use ThereofAug 24, 2021 · US 11,097,013Granted
- Hydrazinyl-indole Compounds And Methods For Producing A ConjugateJan 12, 2021 · US 10,888,623Granted
- Hydrazinyl-pyrrolo Compounds And Methods For Producing A ConjugateMar 31, 2020 · US 10,604,483Granted
- Antibody Specific For CD22 And Methods Of Use ThereofNov 21, 2019 · Application 16289177Pending
- Hydrazinyl-pyrrolo Compounds And Methods For Producing A ConjugateNov 5, 2019 · US 10,464,894Granted
- Hydrazinyl-Indole Compounds and Methods for Producing a ConjugateJun 11, 2019 · US 10,314,919Granted
- Antibody Specific for CD22 and Methods of Use ThereofApr 16, 2019 · US 10,259,871Granted
- Aldehyde-Tagged Immunoglobulin Polypeptides and Methods of Use ThereofJan 22, 2019 · US 10,183,998Granted
- Anti-Her2 Antibody-Maytansine Conjugates and Methods of Use ThereofNov 13, 2018 · US 10,124,070Granted
- Aldehyde-Tagged Protein-Based Drug Carriers and Methods of UseJan 30, 2018 · US 9,879,249Granted
- Hydrazinyl-indole Compounds And Methods For Producing A ConjugateDec 5, 2017 · US 9,833,515Granted
- Compounds And Methods For Producing A ConjugateFeb 28, 2017 · US 9,579,390Granted
- Hydrazinyl-pyrrolo Compounds And Methods For Producing A ConjugateNov 15, 2016 · US 9,493,413Granted
- Hydrazinyl-indole Compounds And Methods For Producing A ConjugateApr 12, 2016 · US 9,310,374Granted
- Antibody Specific for CD22 and Methods of Use ThereofNov 10, 2015 · US 9,181,343Granted
- Aldehyde-tagged Protein-based Drug Carriers And Methods Of UseApplication PCTUS2010024335Pending
- ANTI-HER2 Antibody-maytansine Conjugates And Methods Of Use ThereofApplication PCTUS2015032746Pending
- Hydrazinyl-pyrrolo Compounds And Methods For Producing A ConjugateApplication PCTUS2014067746Pending
- ANTI-HER2 Antibody-maytansine Conjugates And Methods Of Use ThereofApplication 62008980Pending
- Hydrazinyl-pyrrolo Compounds And Methods For Producing A ConjugateApplication 61909897Pending
- Hydrazinyl-indole Compounds And Methods For Producing A ConjugateApplication PCTUS2013070142Pending
- Compounds And Methods For Producing A ConjugateApplication PCTUS2013059267Pending
- Antibody Specific For CD22 And Methods Of Use ThereofApplication PCTUS2013050489Pending
- Hydrazinyl-indole Compounds And Methods For Producing A ConjugateApplication 61727603Pending
- Compounds And Methods For Producing A ConjugateApplication 61725405Pending
- Aldehyde-tagged Immunoglobulin Polypeptides And Methods Of Use ThereofApplication PCTUS2012021367Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .